Artificial Intelligence-Guided Phenotypic Drug Repurposing Against Streptococcus pneumoniae.

Authors

Joshua S Fitch, Muhammad D Ariadi, Min Jung Kwun, Leonie Howells, Saiveth Hernandez-Hernandez, Nicholas J Croucher, Pedro J Ballester

Published in

Advanced science (Weinheim, Baden-Wurttemberg, Germany). Pages e76959. Sep 16, 2026. Epub Sep 16, 2026.

Abstract

The prevalence of antimicrobial resistance (AMR) within the common bacterial pathogen Streptococcus pneumoniae makes it a priority for the development of new antibiotics. While artificial intelligence (AI) has recently boosted phenotype-based repurposing of drugs for other human pathogens, this remains to be investigated for S. pneumoniae. Thus, we leveraged ensembles of transformer, graph, and tree models, each trained on a set of 1849 actives along with 34 503 inactives, to prospectively examine 6747 drugs. Of 11 selected candidate antibiotics, nine were found to strongly reduce in vitro growth of S. pneumoniae R6, with IC₅₀ values of ≤ 0.4 µg/mL. The most potent drugs, thiostrepton and ceftiofur, had IC₅₀ values of 0.0001 µg/mL (60.1 pM) and 0.0004 µg/mL (764 pM), respectively. Thiostrepton remained highly potent even against multidrug-resistant strains, suggesting it could be effectively deployed to treat common non-invasive S. pneumoniae infection as part of antibiotic stewardship efforts.

PMID:
42745629
Bibliographic data and abstract were imported from PubMed on 16 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.